LY 3971297
Alternative Names: LY-3971297Latest Information Update: 19 Jan 2024
At a glance
- Originator Eli Lilly and Company
- Class Antihypertensives; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypertension; Obesity
Most Recent Events
- 07 Dec 2023 Phase-I clinical trials in Hypertension (In adults, In the elderly) in USA (SC) (NCT06148272)
- 07 Dec 2023 Phase-I clinical trials in Obesity (In adults, In the elderly) in USA (SC) (NCT06148272)
- 28 Nov 2023 Eli Lilly and Company plans a phase I trial for Obesity and Hypertension (In volunteers) in USA and Singapore (SC) (NCT06148272)